Current Opinion and Mechanistic Interpretation of Combination Therapy for Castration-resistant Prostate Cancer

Overview

Journal Asian J Androl

Specialty Urology

Date 2019 Mar 30

PMID 30924449

Citations 13

Authors

Jin Xu

Yun Qiu

Affiliations

Soon will be listed here.

Abstract

Recent advances in genomics technology have led to the massive discovery of new drug targets for prostate cancer; however, none of the currently available therapeutics is curative. One of the greatest challenges is drug resistance. Combinations of therapies with distinct mechanisms of action represent a promising strategy that has received renewed attention in recent years. Combination therapies exert cancer killing functions through either concomitant targeting of multiple pro-cancer factors or more effective inhibition of a single pathway. Theoretically, the combination therapy can improve efficacy and efficiency compared with monotherapy. Although increasing numbers of drug combinations are currently being tested in clinical trials, the mechanisms by which these combinations can overcome drug resistance have yet to be fully understood. The purpose of this review is to summarize recent work on therapeutic combinations in the treatment of castration-resistant prostate cancer and discuss emerging mechanisms underlying drug resistance. In addition, we provide an overview of the current preclinical mechanistic studies on potential therapeutic combinations to overcome drug resistance.

Citing Articles

ACOX2 Serves as a Favorable Indicator Related to Lipid Metabolism and Oxidative Stress for Biochemical Recurrence in Prostate Cancer.

Tan Z, Deng Y, Cai Z, He H, Tang Z, Feng Y J Cancer. 2024; 15(10):3010-3023.

PMID: 38706909 PMC: 11064250. DOI: 10.7150/jca.93832.

A review focusing on the role of pyroptosis in prostate cancer.

Liu Z, Kuang S, Chen Q Medicine (Baltimore). 2023; 102(50):e36605.

PMID: 38115248 PMC: 10727670. DOI: 10.1097/MD.0000000000036605.

Anticancer Effect of Dihydroartemisinin Dual Control of ROS-induced Apoptosis and Protective Autophagy in Prostate Cancer 22Rv1 Cells.

Yang J, Xia T, Zhou S, Liu S, Pan T, Li Y Curr Pharm Biotechnol. 2023; 25(10):1321-1332.

PMID: 37605406 DOI: 10.2174/1389201024666230821155243.

Jumonji domain-containing protein RIOX2 is overexpressed and associated with worse survival outcomes in prostate cancers.

He C, Liu W, Sun J, Zhang D, Li B Front Oncol. 2023; 13:1087082.

PMID: 36776320 PMC: 9911806. DOI: 10.3389/fonc.2023.1087082.

SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.

Preto A, Matos-Filipe P, Mourao J, Moreira I Gigascience. 2022; 11.

PMID: 36155782 PMC: 9511701. DOI: 10.1093/gigascience/giac087.

References

Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz J . Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017; 9(5):307-318. PMC: 5424862. DOI: 10.1177/1758834017692779. View

Nguyen H, Yang J, Kung H, Shi X, Tilki D, Lara Jr P . Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014; 33(36):4521-30. PMC: 4155805. DOI: 10.1038/onc.2014.25. View

Mahipal A, Malafa M . Importins and exportins as therapeutic targets in cancer. Pharmacol Ther. 2016; 164:135-43. DOI: 10.1016/j.pharmthera.2016.03.020. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

James N, Sydes M, Clarke N, Mason M, Dearnaley D, Anderson J . Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 2008; 103(4):464-9. DOI: 10.1111/j.1464-410X.2008.08034.x. View

Xu J, Qiu Y . Role of androgen receptor splice variants in prostate cancer metastasis. Asian J Urol. 2017; 3(4):177-184. PMC: 5325179. DOI: 10.1016/j.ajur.2016.08.003. View

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

10.

Xie Y, Xu K, Linn D, Yang X, Guo Z, Shimelis H . The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2007; 283(6):3349-3356. DOI: 10.1074/jbc.M707773200. View

11.

Kodumudi K, Woan K, Gilvary D, Sahakian E, Wei S, Djeu J . A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010; 16(18):4583-94. PMC: 3874864. DOI: 10.1158/1078-0432.CCR-10-0733. View

12.

Lai K, Huang C, Chang Y, Chung C, Yamashita S, Li L . New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2012; 182(2):460-73. PMC: 3562731. DOI: 10.1016/j.ajpath.2012.10.029. View

13.

Dehm S, Tindall D . Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006; 99(2):333-44. DOI: 10.1002/jcb.20794. View

14.

De Gendt K, Denolet E, Willems A, Daniels V, Clinckemalie L, Denayer S . Expression of Tubb3, a beta-tubulin isotype, is regulated by androgens in mouse and rat Sertoli cells. Biol Reprod. 2011; 85(5):934-45. PMC: 4480425. DOI: 10.1095/biolreprod.110.090704. View

15.

Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View

16.

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

17.

Banuelos C, Tavakoli I, Tien A, Caley D, Mawji N, Li Z . Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain. J Biol Chem. 2016; 291(42):22231-22243. PMC: 5064002. DOI: 10.1074/jbc.M116.734475. View

18.

Xiao L, Tien J, Vo J, Tan M, Parolia A, Zhang Y . Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer Res. 2018; 78(20):5731-5740. PMC: 6191320. DOI: 10.1158/0008-5472.CAN-18-0941. View

19.

Morris M, Rathkopf D, Novotny W, Gibbons J, Peterson A, Khondker Z . Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016; 22(15):3774-81. PMC: 5468167. DOI: 10.1158/1078-0432.CCR-15-2638. View

20.

Pawar A, Gollavilli P, Wang S, Asangani I . Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. Cell Rep. 2018; 22(9):2236-2245. DOI: 10.1016/j.celrep.2018.02.011. View